Linnaeus Therapeutics, Inc

Our Mission: Linnaeus Therapeutics aims to turn real-world human biology into medicines that restore resilience against cancer, cardiometabolic diseases, and aging. We start from observed sex differences to identify mechanisms like GPER activation that link tumor suppression, vascular health, metabolism, and brain function. Our mission is not only to develop GPER-targeted therapies, but also to advance and openly share the tools, data, and measures that define how these interventions change the trajectory of aging. Our Company: Linnaeus Therapeutics was founded in 2016 by Christopher Natale, PhD, and Todd Ridky, MD, PhD at the University of Pennsylvania, to bring discoveries on GPER activation to patients. We are advancing LNS8801 through clinical trials in oncology, while building a pipeline in cardiometabolic disease and expansion into aging biology. We are supported by experienced leadership, venture investment, and substantial competitive, nondilutive funding from federal grants